News, Articles and Updates
News
XRHealth Deepens Mental Health Capabilities with Acquisition of PursueCare
XRHealth, a telehealth company that offers virtual reality (VR) therapy for mental health conditions and pain management, has entered the addiction care space with its acquisition of virtual provider PursueCare. The company has been on an M&A tear recently, with this transaction marking the second…
Matching Clinician and Patient Traits to Improve the Therapeutic Alliance
How can clinicians strengthen the therapeutic alliance? — From Psychiatric Times articles Read More
California to fund up to $4M in psychedelic treatment research for veterans
California will award up to $4 million for psychedelic treatment research involving veterans. The California Initiative for Precision Medicine, part of the California Health and Human Services Agency, opened a request for applications to fund partnerships between the state’s nonprofit academic research institutions and veteran…
AI chatbot alone ‘may be insufficient’ for maternal mental health: 6 study notes
Pregnant and postpartum individuals who used a generative AI maternal health chatbot the most reported higher anxiety scores. Overall, the tool did not improve anxiety or depression, according to a University of Maryland-led randomized clinical trial published Nov. 4 in JAMA Network Open. Elizabeth Norell,…
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms. — From Psychiatric Times articles Read More
Atrium Health commits $5M to help open 48 pediatric behavioral beds
Charlotte, N.C.-based Atrium Health is committing $5 million over three years to help the Katie Blessing Center open 48 acute inpatient pediatric behavioral health beds in east Charlotte. The commitment covers operational and consultative services and in-kind support for the beds, serving children and adolescents…
J&J’s Caplyta succeeds in 2nd phase 3 bipolar mania trial
Caplyta, a Johnson & Johnson drug, met its primary and key secondary endpoints in a second pivotal phase 3 trial evaluating it for manic episodes in adults with bipolar I disorder. Study 452 found that Caplyta significantly reduced manic symptoms and overall illness severity compared…
Preventing Schizophrenia Relapse in Women: What You Need to Know
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing. — From Psychiatric Times articles Read More
A Veterans Day Salute: Lessons From 1918 and 2026 for Psychiatrists
Psychiatric Times honors those who served with reflections from a World War I diary and new studies on veteran PTSD and suicide risk. — From Psychiatric Times articles Read More
Five Adjunctive Antipsychotics Compared: Tolerability, Tapering, and Deprescribing
With five adjunctive atypical antipsychotics now approved for MDD, tolerability differences do most of the deciding. The panel matches specific side-effect profiles to individual patients and raises when tapering should begin. — From Psychiatric Times articles Read More
The Best Medication Is the One Patients Take: Weighing Augmentation Risks
Modest efficacy gains from switching push many clinicians toward augmentation instead. The panel weighs guideline thresholds, side-effect-driven medication matching, and the polypharmacy risks that complicate adding a second agent. — From Psychiatric Times articles Read More
Transitivity and Treatment-Effect Modifiers in Network Meta-Analysis of Co-Occurring ADHD and Stimulant Use Disorder: Reply to Yen and Shan
Original Source: Journal of Clinical Psychiatry, all rights reserved. — See letter by Yen and Shan and article by Oliva et al To the Editor: We thank Drs Yen and Shan for their thoughtful comments1 on our network meta-analysis2 of pharmacotherapies for co-occurring stimulant use…
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT